Association of SDOH with mortality after allo-HCT (n = 315)
| Variable . | Hazard ratio . | 95% CI . | P value . | Global P value . |
|---|---|---|---|---|
| Median income | 1.00 | 1.00-1.00 | .558 | |
| Proportion with less than a high school education | 1.18 | 0.87-1.60 | .283 | |
| Proportion below federal poverty level | 1.04 | 0.79-1.36 | .804 | |
| Proportion on SNAP | 1.13 | 0.92-1.38 | .240 | |
| Proportion spending ≥30% of their income on housing | 1.03 | 0.78-1.35 | .845 | |
| Proportion with a second mortgage or a home equity loan | 0.99 | 0.73-1.36 | .970 | |
| Proportion on SSI | 1.21 | 0.81-1.82 | .345 | |
| Proportion driving to work alone | 0.96 | 0.85-1.10 | .570 | |
| Race | ||||
| White | 1 | --- | .722 | |
| Asian | 0.91 | 0.40-2.09 | ||
| Black | 0.98 | 0.45-2.17 | ||
| Other | 0.44 | 0.11-1.80 | ||
| Race∗ | ||||
| White | 1 | --- | .528 | |
| Asian | 0.80 | 0.35-1.81 | ||
| Black | 0.77 | 0.36-1.65 | ||
| Other | 0.41 | 0.10-1.65 |
| Variable . | Hazard ratio . | 95% CI . | P value . | Global P value . |
|---|---|---|---|---|
| Median income | 1.00 | 1.00-1.00 | .558 | |
| Proportion with less than a high school education | 1.18 | 0.87-1.60 | .283 | |
| Proportion below federal poverty level | 1.04 | 0.79-1.36 | .804 | |
| Proportion on SNAP | 1.13 | 0.92-1.38 | .240 | |
| Proportion spending ≥30% of their income on housing | 1.03 | 0.78-1.35 | .845 | |
| Proportion with a second mortgage or a home equity loan | 0.99 | 0.73-1.36 | .970 | |
| Proportion on SSI | 1.21 | 0.81-1.82 | .345 | |
| Proportion driving to work alone | 0.96 | 0.85-1.10 | .570 | |
| Race | ||||
| White | 1 | --- | .722 | |
| Asian | 0.91 | 0.40-2.09 | ||
| Black | 0.98 | 0.45-2.17 | ||
| Other | 0.44 | 0.11-1.80 | ||
| Race∗ | ||||
| White | 1 | --- | .528 | |
| Asian | 0.80 | 0.35-1.81 | ||
| Black | 0.77 | 0.36-1.65 | ||
| Other | 0.41 | 0.10-1.65 |
Each row represents 1 model for 1 SDOH variable adjusted for age and HCT-CI; each as a continuous linear variable; relapsed/refractory AML vs newly diagnosed, intermediate vs unfavorable cytogenetics, status at HCT (CR1 vs other), and intensity of induction therapy.
Unadjusted model (univariate analysis).